Mycofenolate Mofetil versus Standard of Care for COVID Related Interstitial Lung Disease
Phase 2
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2021/11/037872
- Lead Sponsor
- Institute of Postgraduate Medical Education and Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
RT-PCR confirmed case of COVID 19 infection.
Patients with confirmed case of COVID 19 with persistence of lung lesion on HRCT after 6weeks of infection
Normal hepatic and renal function
Participants can understand the study and sign informed consent for the study.
Exclusion Criteria
Previous or concurrent malignancies
Any previous immunosuppressive therapy/ radiotherapy/ or HIV
Medical or psychiatric conditions that compromise the patients ability to give informed consent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in 6 minutesâ?? walk test at 3, 6 and 12 months after therapy. <br/ ><br>Change in FVC at 3,6 and 12 months after therapy. <br/ ><br>Radiological resolution at 6th and 12 months of therapy <br/ ><br>Timepoint: Baseline, 3, 6 and 12 months
- Secondary Outcome Measures
Name Time Method HAQ <br/ ><br>Prevalence of infections in different groups <br/ ><br>Timepoint: 3, 6, and 12 months